About Dr. Gerald Chan
In 1986, Dr. Gerald Chan co-founded Morningside. Morningside makes venture capital investments in companies with novel science and technology, and is characterized by a long-term outlook in company-building and an unwavering commitment to acting ethically.
Dr. Chan chairs the boards of two Nasdaq listed biotech companies, Apellis Pharmaceuticals and Stealth BioTherapeutics and is a board member of privately held companies Apnimed, Matrivax and CollegeVine. He is a trustee of Scripps Research Institute in La Jolla, California, and a member of the Dean’s Board of Advisors of the Harvard T.H. Chan School of Public Health. Dr. Chan also chaired the Innovation Advisory Committee of the Wellcome Trust in London and the Committee of Overseers of Morningside College of Chinese University of Hong Kong.
Dr. Chan received his BS and MS degrees in Engineering from UCLA, a Master of Science degree in Medical Radiological Physics, and a Doctor of Science degree in Radiation Biology from Harvard University. He completed his post-doctoral training in pathology at the Harvard Medical School and Dana-Farber Cancer Institute. He holds an honorary fellowship at Wolfson College of Oxford University and was elected to membership in the American Academy of Arts and Sciences. In 2019, he was Visiting Fellow at Trinity College, Cambridge University and gave the Andrew Carnegie Lecture in University of Glasgow.